Last reviewed · How we verify
NCT05909228
Bone Markers in Pediatric IF
trial in Intestinal Failure in 35 participants. Completed in 30 September 2023.
30 September 2023
Quick facts
| Lead sponsor | The Hospital for Sick Children |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 35 |
| Start date | 31 March 2023 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across Canada |
Conditions studied
- Intestinal Failure — all drugs for Intestinal Failure →
- Osteoporosis — all drugs for Osteoporosis →
- Metabolic Bone Disease — all drugs for Metabolic Bone Disease →
Sponsor
The Hospital for Sick Children
Who can join
Adults 6 Weeks to 18, any sex, with Intestinal Failure or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Poor bone health is a well-recognized but poorly understood complication in children with intestinal failure (IF) who are dependent on parenteral nutrition (PN). Previously, we showed that children with IF have decreased bone turnover markers. It is currently unknown if optimization of parenteral nutrition is related to improved bone turnover markers. Serum concentrations of bone markers (osteocalcin, bone-specific alkaline phosphatase and c-telopeptide) will be measured in 30 IF patients treated at a multidisciplinary intestinal rehabilitation and home PN program at the Hospital for Sick Children and compared to bone markers in 30 age- and sex-matched healthy controls.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05909228
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intestinal Failure
Currently open trials in the same condition.
- NCT07297238 — Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. · NA · recruiting
- NCT07414576 — AI-driven Total Parenteral Nutrition Platform · NA · recruiting
- NCT06525753 — Weaning is Winning? (WeWin Study) · recruiting
- NCT06777251 — Changing the Future of Intestinal Failure in Intestinal Chronic Inflammation (INT-FAIL) · NA · active not recruiting
- NCT06169774 — Video Training Supplementation for Patients Discharged on Home Parental Nutrition · NA · recruiting
Other The Hospital for Sick Children trials
Trials by the same sponsor.
- NCT07454681 — MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure . · not yet recruiting
- NCT07452575 — 3D Ultrasound in Hemophilic Ankles · NA · not yet recruiting
- NCT07508826 — AI-assisted Endotracheal Intubation · NA · not yet recruiting
- NCT07345819 — Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis · NA · not yet recruiting
- NCT07497178 — MRgFUS for Childhood Epilepsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05909228 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hospital for Sick Children
- Last refreshed: 16 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909228.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing